Immune-Cell-Based Therapy for COVID-19: Current Status

Yiyuan Wang; Qinghe Liang; Fengsheng Chen; Jiehuang Zheng; Yan Chen; Ziye Chen; Ruopeng Li; Xiaojuan Li

doi:10.3390/v15112148

Immune-Cell-Based Therapy for COVID-19: Current Status

Viruses. 2023 Oct 25;15(11):2148. doi: 10.3390/v15112148.

Authors

Yiyuan Wang^{1

2

3}, Qinghe Liang^{1

2

3}, Fengsheng Chen^{1

2

3}, Jiehuang Zheng^{1

2

3}, Yan Chen^{1

2

3}, Ziye Chen^{1

2

3}, Ruopeng Li^{1

2

3}, Xiaojuan Li^{1

2

3}

Affiliations

¹ Laboratory of Anti-Inflammatory and Immunomodulatory Pharmacology, Innovation Program of Drug Research on Inflammatory and Immune Diseases, Southern Medical University, Guangzhou 510515, China.
² NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
³ Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic. The interplay between innate and adaptive immune responses plays a crucial role in managing COVID-19. Cell therapy has recently emerged as a promising strategy to modulate the immune system, offering immense potential for the treatment of COVID-19 due to its customizability and regenerative capabilities. This review provides an overview of the various subsets of immune cell subsets implicated in the pathogenesis of COVID-19 and a comprehensive summary of the current status of immune cell therapy in COVID-19 treatment.

Keywords: COVID-19; SARS-CoV-2; cell therapy; immunotherapy.

Publication types

Review

MeSH terms

COVID-19 Drug Treatment
COVID-19* / therapy
Cell- and Tissue-Based Therapy
Humans
Immunity, Innate
Immunotherapy
SARS-CoV-2

Abstract

Publication types

MeSH terms

Grants and funding